Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
1194MO Canakinumab (CAN) + docetaxel (DTX) for the second- or third-line (2/3L) treatment of advanced non-small cell lung cancer (NSCLC): CANOPY-2 phase III results
PaperCitations, authors & open-access status
1194MO Canakinumab (CAN) + docetaxel (DTX) for the second- or third-line (2/3L) treatment of advanced non-small cell lung cancer (NSCLC): CANOPY-2 phase III results is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 27 citations, 2021 year and bronze oa status.
27
Citations
2021
Year
bronze
OA Status